Table 1.

Combination study for nab-paclitaxel and LY2090314.

CI25 (±SD)CI50 (±SD)CI75 (±SD)DRIIC25 nab-paclitaxelDRIIC50 nab-paclitaxelDRIIC75 nab-paclitaxelDRIIC25 LY2090314DRIIC50 LY2090314DRIIC75 LY2090314r
AsPC11.6 ± 0.50.59 ± 0.10.77 ± 0.30.62.127.140.27.91.60.99
PANC10.44 ± 0.060.35 ± 0.040.47 ± 0.082.85.912.712.55.62.50.99
MDA-Panc280.19 ± 0.10.25 ± 0.120.37 ± 0.245.942.660.51,22324,8000.98
  • Abbreviations: CI, combination index; DRI, dose reduction index; ED, effect dose; r, linear correlation coefficient.